EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Natural killer cell‐related anti‐tumour adoptive cell immunotherapy

Yuwen Qi, Ying Li, Hua Wang, Anjin Wang, Xuelian Liu, Ziyan Liang, Yang Gao iD, Liqing Wei iD

Journal of Cellular and Molecular Medicine · 2024-06 · 28 (11)

DOI: 10.1111/jcmm.18362 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 05.06.2024. Verfasst von Yuwen Qi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Killer Cells, Natural, Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund, The Fundamental Research Funds for the Central Universities, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor‐ (CAR‐)modified T cells have been successfully used to treat blood cancer. With the improved research on anti‐tumour adoptive cell therapy, researchers have focused on immune cells other than T lymphocytes. Natural killer (NK) cells have received widespread attention as barriers to natural immunity. Compared to T lymphocyte‐related adoptive cell therapy, the use of NK cells to treat tumours does not cause graft‐versus‐host disease, significantly improving immunity. Moreover, NK cells have more sources than T cells, and the related modified cells are less expensive. NK cells function through several pathways in anti‐tumour mechanisms. Currently, many anti‐tumour clinical trials have used NK cell‐related adoptive cell therapies. In this review, we have summarized the recent progress in NK cell‐related adoptive cellular immunotherapy for tumour treatment and propose the current challenges faced by CAR‐NK cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveKiller Cells, NaturalNeoplasmsReceptors, Chimeric AntigenHumansAnimals

Stichwörter der Autor:innen

challengeschimeric antigen receptor (CAR)‐T cellimmunotherapynatural killer (NK) cells

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.
  • Hubei Cancer Clinical Study Center, Wuhan, China.
  • Physical Examination Center, Renmin Hospital of Wuhan University, Wuhan, China.
  • Wuhan Wuchang Hospital, Wuhan University of Science and Technology, Wuhan, China.

ORCID-Profile: Yang Gao, Liqing Wei

Förderung

  • Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund
  • The Fundamental Research Funds for the Central Universities
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Qi, Y., Li, Y., Wang, H., Wang, A., Liu, X., Liang, Z., Gao, Y., & Wei, L. (2024). Natural killer cell‐related anti‐tumour adoptive cell immunotherapy. Journal of Cellular and Molecular Medicine, 28(11). https://doi.org/10.1111/jcmm.18362

Vancouver

Qi Y, Li Y, Wang H, Wang A, Liu X, Liang Z, et al. Natural killer cell‐related anti‐tumour adoptive cell immunotherapy. Journal of Cellular and Molecular Medicine. 2024;28(11). doi:10.1111/jcmm.18362

BibTeX
@article{Qi2024,
  author = {Qi, Yuwen and Li, Ying and Wang, Hua and Wang, Anjin and Liu, Xuelian and Liang, Ziyan and Gao, Yang and Wei, Liqing},
  title = {Natural killer cell‐related anti‐tumour adoptive cell immunotherapy},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  volume = {28},
  number = {11},
  doi = {10.1111/jcmm.18362}
}
Kostenlos starten →